Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
OHE Models Incentives for Antibiotic Drug Development
18 March 2014
The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing…
Defining the Complementarity of Medical Research Across Sectors in the UK
11 March 2014
Under an MRC grant, OHE is collaborating to estimate in monetary terms the synergies of medical research spending in the UK by the pharma industry, charities…
Benefiting from the Promise of Personalised Medicine: Recent OHE Presentations
18 February 2014
Focusing on England, these two presentations describe the core economic considerations in making the most of targeted therapy. OHE’s Adrian Towse participated in a two-day workshop…
Exploring the Interdependencies of Research Funders in the UK
1 July 2014
As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their…
The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness
1 April 2014
The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen,…
Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
18 December 2013
Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in…
OHE Involved in Developing New AMS Report on Stratified Medicines
15 July 2013
Professor Adrian Towse, OHE’s Director, joined Professor Sir John Bell and Professor Andrew Morris at the Science Media Centre last week to launch Realising the Potential…
Forecasting the Challenges and Economics of Drug Development in 2022
9 July 2013
A new publication from the Office of Health Economics captures the views of thought leaders from around the world about the scientific and economic climate for…
Critical Factors Affecting Pharmaceutical R&D and the Availability of New Drugs
18 June 2013
Dr Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence…